Patent · US Active

Interleukin-12p40 variants with improved stability

US7872107B2 · kind B2 · utility

10Cited by

53References

29Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Gordon D. Webster · Greenville, US
Suzanne P. McKenzie · Newton, US
Kin-Ming Lo · Lexington, US
Pascal André Stein · Boston, US

Key dates

Filing date	Dec 29, 2006
Grant date	Jan 18, 2011
Priority date	—
Expiry date	Aug 9, 2027

Classification

Technology area (CPC H)Electricity
CPC primaryH04L41/5019
WIPO fieldAudio-visual technology
WIPO sectorElectrical engineering

Abstract

Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.